Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics

Anti-inflammatory effects of seven years treatment with Omalizumab in severe uncontrolled asthmatics

(2010) E. Pace et al.   ALLERGY

Effects of omalizumab on markers of inflammation in patients with allergic asthma

(2009) S. Holgate et al.   ALLERGY

After 6 years with Xolair; a 3-year withdrawal follow-up

(2009) A. Nopp et al.   ALLERGY

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

(2009) Raymond G. Slavin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Non-invasive markers of airway inflammation and remodeling in childhood asthma

(2009) Rosalia Gagliardo et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study

(2009) G. Brusselle et al.   RESPIRATORY MEDICINE

Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment

(2008) E. L. J. van Rensen et al.   ALLERGY

Etiology of asthma exacerbations

(2008) Annemarie Sykes et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Immunomodulatory and biologic therapies for severe refractory asthma

(2008) Riccardo Polosa et al.   RESPIRATORY MEDICINE

Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma

(2007) Joanne Shannon et al.   CHEST